These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 18552464)

  • 1. The efficacy of short-term interferon-beta therapy for type C cirrhotic patients with genotype 2a and low virus load.
    Arase Y; Suzuki F; Sezaki H; Kawamura Y; Suzuki Y; Kobayashi M; Akuta N; Hosaka T; Yatsuji H; Kobayashi M; Saitoh S; Ikeda K; Kumada H
    Intern Med; 2008; 47(12):1085-90. PubMed ID: 18552464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The efficacy of 24-week interferon monotherapy for type C liver cirrhosis in Japanese patients with genotype 1b and low virus load.
    Arase Y; Suzuki F; Sezaki H; Kawamura Y; Suzuki Y; Kobayashi M; Akuta N; Hosaka T; Yatsuji H; Hirakawa M; Kobayashi M; Ikeda K; Kumada H
    Intervirology; 2008; 51(4):265-9. PubMed ID: 18841028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The efficacy of short-term interferon-beta therapy for chronic hepatitis C patients with low virus load.
    Kawamura Y; Arase Y; Ikeda K; Suzuki F; Suzuki Y; Kobayashi M; Akuta N; Hosaka T; Sezaki H; Yatsuji H; Kobayashi M; Kumada H
    Intern Med; 2008; 47(5):355-60. PubMed ID: 18310963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of combination therapy of natural human interferon beta and ribavirin in chronic hepatitis C patients with genotype 1b and high virus load.
    Arase Y; Suzuki F; Akuta N; Sezaki H; Suzuki Y; Kawamura Y; Kobayashi M; Hosaka T; Yatsuji H; Hirakawa M; Saito S; Ikeda K; Kobayashi M; Kumada H
    Intern Med; 2010; 49(11):957-63. PubMed ID: 20519809
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of combination therapy of natural human interferon beta and ribavirin in chronic hepatitis C patients with genotype 2 and high virus load.
    Arase Y; Suzuki F; Akuta N; Sezaki H; Suzuki Y; Kawamura Y; Kobayashi M; Hosaka T; Yatsuji H; Hirakawa M; Matsumoto N; Saito S; Ikeda K; Kobayashi M; Kumada H
    Intern Med; 2010; 49(11):965-70. PubMed ID: 20519810
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy of interferon-beta monotherapy for elderly patients with type C hepatitis of genotype 2.
    Arase Y; Suzuki F; Sezaki H; Kawamura Y; Suzuki Y; Kobayashi M; Akuta N; Hosaka T; Yatsuji H; Hirakawa M; Kobayashi M; Saitoh S; Ikeda K; Kumada H
    Intern Med; 2009; 48(16):1337-42. PubMed ID: 19687576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatitis C virus genotypes and hepatic fibrosis regulate 24-h decline of serum hepatitis C virus RNA during interferon therapy in patients with chronic hepatitis C.
    Karino Y; Toyota J; Sugawara M; Miyazaki K; Kuwata Y; Yamazaki K; Sato T; Ohmura T; Matsushima T
    J Gastroenterol Hepatol; 2003 Apr; 18(4):404-10. PubMed ID: 12653888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of short-term interferon therapy for patients infected with hepatitis C virus genotype 2a.
    Tabaru A; Narita R; Hiura M; Abe S; Otsuki M
    Am J Gastroenterol; 2005 Apr; 100(4):862-7. PubMed ID: 15784033
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A pilot study of combination therapy with initial high-dose interferon and amantadine hydrochloride for patients with chronic hepatitis C with the genotype 1b virus.
    Uyama H; Enomoto H; Kishima Y; Yamamoto M; Yoshida K; Okuda Y; Hirotani T; Kuroda T; Ito H; Matsuda M; Terabayashi M; Noguchi S; Kawase I; Nakamura H
    Hepatogastroenterology; 2003; 50(54):2112-6. PubMed ID: 14696476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination therapy of peginterferon and ribavirin for chronic hepatitis C patients with genotype 1b and low-virus load.
    Arase Y; Suzuki F; Akuta N; Sezaki H; Suzuki Y; Kawamura Y; Kobayashi M; Hosaka T; Yatsuji H; Hirakawa M; Saito S; Ikeda K; Kobayashi M; Kumada H
    Intern Med; 2009; 48(5):253-8. PubMed ID: 19252344
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interferon treatment for patients with chronic hepatitis C infected with high viral load of genotype 2 virus.
    Nakamura H; Ogawa H; Kuroda T; Yamamoto M; Enomoto H; Kishima Y; Yoshida K; Ito H; Matsuda M; Noguchi S
    Hepatogastroenterology; 2002; 49(47):1373-6. PubMed ID: 12239945
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of combination therapy of natural human interferon beta and ribavirin in chronic hepatitis C patients.
    Arase Y; Suzuki Y; Suzuki F; Matsumoto N; Akuta N; Imai N; Seko Y; Sezaki H; Kawamura Y; Kobayashi M; Hosaka T; Saito S; Ikeda K; Kobayashi M; Kumada H
    Intern Med; 2011; 50(19):2083-8. PubMed ID: 21963723
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Viral kinetic of HCV genotype-4 during pegylated interferon alpha 2a: ribavirin therapy.
    Derbala MF; El Dweik NZ; Al Kaabi SR; Al-Marri AD; Pasic F; Bener AB; Shebl FM; Amer AM; Butt MT; Yakoob R; John A; Al Mohanadi M; Al Khinji MA
    J Viral Hepat; 2008 Aug; 15(8):591-9. PubMed ID: 18482284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early virological response may predict treatment response in sofosbuvir-based combination therapy of chronic hepatitis c in a multi-center "real-life" cohort.
    Steinebrunner N; Sprinzl MF; Zimmermann T; Wörns MA; Zimmerer T; Galle PR; Stremmel W; Eisenbach C; Stein K; Antoni C; Schattenberg JM; Pathil A
    BMC Gastroenterol; 2015 Aug; 15():97. PubMed ID: 26239732
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of virus genotype on interferon treatment of patients with chronic hepatitis C: a multicenter controlled study.
    Xie Y; Xu DZ; Lu ZM; Luo KX; Jia JD; Wang YM; Zhao GZ; Zhang SL; Zhang DZ
    Hepatobiliary Pancreat Dis Int; 2004 Aug; 3(3):369-74. PubMed ID: 15313671
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive value of on-treatment response during full-dose antiviral therapy of patients with hepatitis C virus cirrhosis and portal hypertension.
    Giannini EG; Basso M; Savarino V; Picciotto A
    J Intern Med; 2009 Dec; 266(6):537-46. PubMed ID: 19849774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of the efficacy of intravenous natural interferon-beta treatment in chronic hepatitis C.
    Fukutomi T; Fukutomi M; Iwao M; Watanabe H; Tanabe Y; Hiroshige K; Kinukawa N; Nakamuta M; Nawata H
    Med Sci Monit; 2000; 6(4):692-8. PubMed ID: 11208393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment effects and predictors of a 24-week course of interferon alpha-2b plus ribavirin combination therapy for patients with chronic hepatitis C.
    Tomimatsu M; Aizawa Y; Chuganji Y; Ishizuka H; Fujita Y; Aizawa R; Abe H; Matsuda T; Itou Y; Nakanishi H; Ushiyama H; Higuchi T; Fujimoto T; Endou H; Iga D; Ohta K; Kuroda H
    J Gastroenterol Hepatol; 2006 Jul; 21(7):1177-83. PubMed ID: 16824072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Boceprevir is highly effective in treatment-experienced hepatitis C virus-positive genotype-1 menopausal women.
    Bernabucci V; Ciancio A; Petta S; Karampatou A; Turco L; Strona S; Critelli R; Todesca P; Cerami C; Sagnelli C; Rizzetto M; Cammà C; Villa E
    World J Gastroenterol; 2014 Nov; 20(44):16726-33. PubMed ID: 25469044
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Higher rate of sustained virologic response in chronic hepatitis C genotype 6 treated with 48 weeks versus 24 weeks of peginterferon plus ribavirin.
    Nguyen MH; Trinh HN; Garcia R; Nguyen G; Lam KD; Keeffe EB
    Am J Gastroenterol; 2008 May; 103(5):1131-5. PubMed ID: 18477343
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.